Q-omics provides the consensus-scored CBX1P1 profile across patient tissues and cancer cell-line models. CBX1P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CBX1P1 is differentially expressed in 7, with the highest sampling consensus in UCEC. Additionally, CBX1P1 RNA expression shows 13,531 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, UCEC, and THYM as cancer lineages where CBX1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX1P1 survival associations across molecular data types. CBX1P1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX1P1 RNA expression–survival associations across cancer types. High CBX1P1 expression shows unfavorable associations in MESO, LGG and DLBC, but favorable associations in UCS, THCA and READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for CBX1P1 RNA expression.
This table summarizes CBX1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for CBX1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX1P1 shows lower tumor expression in UCEC, BLCA, BRCA and THCA and higher tumor expression in LUAD and COAD. The UCEC box plot shows higher CBX1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.333, t-test p = .018).
This table shows molecular features associated with CBX1P1 in patient tissues and cancer cell lines. In patient samples, CBX1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
